Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Clin Oncol (R Coll Radiol). 2014 Mar;26(3):135-41. doi: 10.1016/j.clon.2013.10.007. Epub 2013 Nov 15.

Panitumumab monotherapy as a second-line treatment in metastasised colorectal cancer: a single centre experience.

Author information

  • 1Catharina Hospital Eindhoven, Eindhoven, The Netherlands. Electronic address: Irene.v.hellemond@catharinaziekenhuis.nl.
  • 2Catharina Hospital Eindhoven, Eindhoven, The Netherlands.
  • 3Amgen BV, Breda, The Netherlands; Merck Serono, Darmstadt, Germany.
  • 4Catharina Hospital Eindhoven, Eindhoven, The Netherlands; St Radboud University Medical Centre, Nijmegen, The Netherlands.



To report our clinical experience of panitumumab monotherapy as a second-line treatment for patients with metastatic colorectal cancer (mCRC).


This retrospective, descriptive study included a series of consecutive patients receiving panitumumab monotherapy (6 mg/kg 2 weekly) at a single centre in the Netherlands between June 2009 and November 2011. All patients had wild-type KRAS tumours, had progressed during first-line fluoropyrimidine-based therapy and were not candidates for, or refused, standard second-line therapy (usually irinotecan in the Netherlands). Prophylactic medication was given for epidermal growth factor receptor inhibitor-associated skin toxicities.


Thirty-one patients were treated during this period. The most commonly administered first-line mCRC regimen was capecitabine/oxaliplatin/bevacizumab (18/31 patients; 58.1%). Patients received a mean of 7.9 (range 1-18) panitumumab cycles. The median progression-free survival was 3.4 (95% confidence interval 2.4, 4.4) months. The median overall survival estimates were 11.4 (95% confidence interval 1.2, 21.6) months from the initiation of panitumumab monotherapy. Ten patients experienced partial responses according to Response Evaluation Criteria In Solid Tumors (RECIST; objective response rate: 32.3%); disease was controlled (objective response or stable disease) in 15 patients (48.4%). Carcinoembryonic antigen (CEA) responses (two consecutive ≥10% decreases from baseline) occurred in 11/29 patients (37.9%); all of whom had >50% decreases in CEA levels. All patients with an objective response at week 12 had CEA reductions at weeks 6 and 12. The only adverse events were grade 1/2 skin toxicities (61.3%) and gastrointestinal complaints (6.5%); three other patients (9.7%) experienced both skin and gastrointestinal complaints.


Panitumumab monotherapy seems to be a safe and active second-line treatment for patients with wild-type KRAS mCRC, with activity in line with that seen for irinotecan monotherapy, but with less toxicity. CEA may provide a useful early indicator of response to panitumumab.

Copyright © 2013 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.


Carcinoembryonic antigen; Metastatic colorectal cancer; Monotherapy; Panitumumab; Response

[PubMed - in process]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk